Stephen Curtis
InvestorInterim VP, Innovation & Impact Investing and Managing Director at BrightEdge
Boston, Massachusetts
Writes $100K – $5M checks · typically $1.5M
Find your path to Stephen
1,555 people in our graph can introduce you to Stephen.
Each arrow is one introduction. Sign up to fill in the first one.
Ask Detlev Biniszkiewicz to introduce you to Stephen
You →Detlev · together at NextPoint Therapeutics (2019–2026) →Stephen
Ask Jamie Chen to introduce you to Stephen
You →Jamie · 3 people · together at Kauffman Fellows Class 20 →Stephen
Ask Sam Okafor to introduce you to Stephen
You →Sam · together at NextPoint Therapeutics →Stephen
Sign up to find every way you can get introduced to Stephen
- Your email: the people you already email who know Stephen
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with Stephen
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
About
Stephen Curtis is a Kauffman Fellow, a member of Class 20 of the two-year venture capital leadership program run by Kauffman Fellows. The program's member directory lists them at BrightEdge - American Cancer Society in United States.
Experience
- BrightEdge - American Cancer SocietyInterim VP, Innovation & Impact Investing and Managing Directorcurrent2022 — present
- NextPoint Therapeutics, Inc.Strategy / Business Development Consultantcurrent2022 — present
- NextPoint Therapeutics, Inc.Interim COO / Board of Directors2019 — 2022Cambridge, Massachusetts, United States
- Kauffman FellowsCo-Chair - Boston Chapter2015 — 2022
- Kauffman FellowsCo-Chair - Healthcare SIG2015 — 2022
- Kauffman FellowsFellow - Class 202015 — 2017
- MPM CapitalStealth NewCos - Founding Board Member and COO/CBO2018 — 2022Cambridge, Massachusetts, United States
- MPM CapitalManaging Director - Oncology Innovations2018 — 2022Greater Boston
- MPM CapitalPrincipal2018Greater Boston
- Dyne TherapeuticsBoard Observer2018 — 2020Cambridge, Massachusetts, United States
- Eli Lilly and CompanySr Director, Business Development - Emerging Technology and Innovation2017 — 2018Greater Boston
- 2M Companies, Inc.Bioscience Ventures2014 — 2016Dallas-Fort Worth Metroplex
- Reata Pharmaceuticals, Inc.Licensing & Intellectual Property | Biopharmaceutical Leadership Development Program2011 — 2014Irving, TX
- Siemens Venture CapitalMarket Analyst Intern2010 — 2011Boston, MA
- Laboratory of Dr. Carla Kim, Harvard Medical SchoolDoctoral Student2006 — 2011Boston, MA
- Forest Laboratories (now Allergan)Research Assistant2006Commack, NY
- Laboratory of Dr. Alexander Nikitin, Cornell UniversityHonors Research Student2002 — 2006Ithaca, NY
- The Collaborative Group (now a subdivision of BASF)Research Intern2003Stonybrook, NY
Skills & more
+3 more
Molecular BiologyImpact InvestingVenture PhilanthropyFrom Stephen's professional profile.
Colleagues at BrightEdge
Frequently asked questions
- Who is Stephen Curtis?
- Stephen Curtis is a Kauffman Fellow, a member of Class 20 of the two-year venture capital leadership program run by Kauffman Fellows. The program's member directory lists them at BrightEdge - American Cancer Society in United States.
- Where does Stephen Curtis work?
- Stephen Curtis is Interim VP, Innovation & Impact Investing and Managing Director at BrightEdge.
- What check size does Stephen Curtis write?
- Stephen Curtis typically writes checks of $100K – $5M.
- Where did Stephen Curtis go to school?
- Stephen Curtis studied at Harvard Medical School (Doctor of Philosophy (Ph.D.), Biological and Biomedical Sciences); Cornell University (Bachelor of Science (B.S.), Molecular and Cellular Biology; Applied Economics and Management).
Same school
Also attended Harvard Medical School331
+ 325 more
Also attended Cornell University1,510
+ 1,504 more
Shared employers
Also worked at Kauffman Fellows513
+ 507 more
Also worked at Dyne Therapeutics6
Also worked at Eli Lilly and Company198
+ 192 more
Also worked at Reata Pharmaceuticals, Inc.13
+ 7 more

























































